Skip to main content

Table 3 Biodistribution results of 177Lu-SS-03 and 99mTc-SS-04 in nude mice bearing HEK293-rsst2 tumour xenografts. Data expressed as %IA/g (percentage of injected activity per gram) and presented as mean ± SD (n = 3–5)

From: The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist

Organs 1 h 4 h 4 h blocking* 24 h
177Lu-SS-03
 Blood 0.57 ± 0.04 0.21 ± 0.04 0.07 ± 0.02 0.07 ± 0.04
 Heart 0.69 ± 0.12 0.38 ± 0.07 0.11 ± 0.01 0.11 ± 0.04
 Liver 3.00 ± 0.66 1.75 ± 0.22 1.04 ± 0.09 0.47 ± 0.07
 Spleen 1.51 ± 0.19 1.42 ± 0.77 0.28 ± 0.04 0.33 ± 0.06
 Lung 13.24 ± 4.49 6.71 ± 1.37 0.59 ± 0.11 0.74 ± 0.22
 Kidney 15.15 ± 1.86 17.04 ± 1.81 20.24 ± 4.30 7.35 ± 1.66
 Stomach 48.74 ± 13.11 30.21 ± 4.25 0.37 ± 0.06 6.02 ± 1.40
 Intestine 3.13 ± 1.16 2.28 ± 0.31 0.24 ± 0.03 0.27 ± 0.06
 Adrenal 3.70 ± 0.63 2.90 ± 0.46 0.06 ± 0.03 1.16 ± 0.46
 Pancreas 72.61 ± 13.77 54.49 ± 7.28 0.24 ± 0.07 3.03 ± 0.62
 Muscle 0.22 ± 0.06 0.12 ± 0.02 0.06 ± 0.00 0.07 ± 0.02
 Bone 4.11 ± 0.53 2.77 ± 1.06 0.12 ± 0.03 1.25 ± 0.16
 Tumour 23.64 ± 1.28 31.68 ± 4.00 11.15 ± 1.93 26.32 ± 4.42
99mTc-SS-04
 Blood 1.85 ± 0.41 0.22 ± 0.03 0.22 ± 0.01 0.03 ± 0.01
 Heart 1.42 ± 0.30 0.25 ± 0.06 0.23 ± 0.02 0.09 ± 0.01
 Liver 7.18 ± 0.40 5.13 ± 0.51 4.07 ± 0.65 1.87 ± 0.33
 Spleen 2.09 ± 0.34 0.85 ± 0.08 0.63 ± 0.02 0.41 ± 0.11
 Lung 15.93 ± 2.69 2.03 ± 0.14 2.00 ± 0.37 0.54 ± 0.10
 Kidney 49.82 ± 4.31 25.56 ± 1.01 18.48 ± 3.66 6.31 ± 1.82
 Stomach 11.13 ± 2.98 1.99 ± 0.39 0.56 ± 0.03 0.62 ± 0.14
 Intestine 2.12 ± 0.57 0.57 ± 0.06 0.42 ± 0.03 0.16 ± 0.02
 Adrenal 3.17 ± 0.69 0.99 ± 0.20 0.37 ± 0.10 0.50 ± 0.13
 Pancreas 15.58 ± 0.82 1.16 ± 0.86 0.33 ± 0.06 0.31 ± 0.11
 Muscle 0.64 ± 0.13 0.12 ± 0.02 0.12 ± 0.02 0.05 ± 0.03
 Bone 3.15 ± 0.72 0.92 ± 0.15 0.40 ± 0.01 0.44 ± 0.23
 Tumour 47.14 ± 7.23 47.24 ± 7.96 14.17 ± 1.69 32.51 ± 0.78
  1. *Pre-injection with 20 nmol of unlabelled peptide (SS-03 or SS-04)